COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study.
COVID-19
Communicable diseases
Coronavirus
Incidence
Reinfection
Journal
Iranian journal of medical sciences
ISSN: 1735-3688
Titre abrégé: Iran J Med Sci
Pays: Iran
ID NLM: 8104374
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
13
02
2022
revised:
02
05
2022
accepted:
18
05
2022
medline:
5
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
Reinfection with Coronavirus Diseases 2019 (COVID-19) has raised remarkable public health concerns globally. Therefore, the present retrospective cohort study intended to investigate COVID-19 reinfection in registered patients of Fars province in Iran from February 2020 to April 2021. The patients' data, including the COVID-19 infection, symptoms, comorbidities, and demographics, were collected using the Health Information Systems (HISs). The patients were divided into three groups in terms of the duration between the initial infection and reinfection, including 28-44, 45-89, and more than 90 days. Following the univariate analysis, logistic regression was used to investigate the factors effective on COVID-19 reinfection. A total of 213768 patients had a positive Polymerase Chain Reaction (PCR) test. The reinfection rate was 0.97% (2079 patients). Of these re-infected individuals, 14.9%, 18.5%, and 66.6% had their second positive test 28-45, 45-89, and ≥90 days later, respectively. The mean duration between the initial infection and reinfection was 130.56 days (29-370 days). The chance of reinfection was significantly higher in the youths (Odds Ratio (OR)=2.055; P<0.001), men (OR=1.283; P<0.001), urban population (OR=1.313; P<0.001), and healthcare providers (OR=4.453; P<0.001). The patients with chronic pulmonary diseases, chronic kidney diseases, and malignancy were 1.421 (P=0.036), 2.239 (P<0.001), and 3.437 (P<0.001) times, respectively, more likely prone to reinfection. The results of this study showed that there is a higher risk of reinfection in several vulnerable groups including healthcare providers, young individuals, residents of urban areas, men, and individuals with underlying diseases.
Sections du résumé
Background
Reinfection with Coronavirus Diseases 2019 (COVID-19) has raised remarkable public health concerns globally. Therefore, the present retrospective cohort study intended to investigate COVID-19 reinfection in registered patients of Fars province in Iran from February 2020 to April 2021.
Methods
The patients' data, including the COVID-19 infection, symptoms, comorbidities, and demographics, were collected using the Health Information Systems (HISs). The patients were divided into three groups in terms of the duration between the initial infection and reinfection, including 28-44, 45-89, and more than 90 days. Following the univariate analysis, logistic regression was used to investigate the factors effective on COVID-19 reinfection.
Results
A total of 213768 patients had a positive Polymerase Chain Reaction (PCR) test. The reinfection rate was 0.97% (2079 patients). Of these re-infected individuals, 14.9%, 18.5%, and 66.6% had their second positive test 28-45, 45-89, and ≥90 days later, respectively. The mean duration between the initial infection and reinfection was 130.56 days (29-370 days). The chance of reinfection was significantly higher in the youths (Odds Ratio (OR)=2.055; P<0.001), men (OR=1.283; P<0.001), urban population (OR=1.313; P<0.001), and healthcare providers (OR=4.453; P<0.001). The patients with chronic pulmonary diseases, chronic kidney diseases, and malignancy were 1.421 (P=0.036), 2.239 (P<0.001), and 3.437 (P<0.001) times, respectively, more likely prone to reinfection.
Conclusion
The results of this study showed that there is a higher risk of reinfection in several vulnerable groups including healthcare providers, young individuals, residents of urban areas, men, and individuals with underlying diseases.
Identifiants
pubmed: 37791328
doi: 10.30476/IJMS.2022.94615.2598
pii: IJMS-48-3
pmc: PMC10542930
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
302-312Informations de copyright
Copyright: © Iranian Journal of Medical Sciences.
Déclaration de conflit d'intérêts
None declared.
Références
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Clin Infect Dis. 2021 Dec 6;73(11):e4223-e4228
pubmed: 33338197
Cell Host Microbe. 2016 Apr 13;19(4):493-503
pubmed: 27078068
Epidemiol Infect. 2021 Apr 19;149:e159
pubmed: 33866988
J Infect Public Health. 2021 Jun;14(6):685-688
pubmed: 33971576
Emerg Microbes Infect. 2021 Dec;10(1):152-160
pubmed: 33407005
Respir Med. 2020 Jun;167:105941
pubmed: 32421537
Clin Infect Dis. 2021 Jul 15;73(2):354-356
pubmed: 32887979
Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1245-1252
pubmed: 33447913
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
SN Compr Clin Med. 2021;3(2):670-674
pubmed: 33585797
Hematol Transfus Cell Ther. 2021 Jan-Mar;43(1):109-111
pubmed: 33423984
Kidney Med. 2021 May-Jun;3(3):447-450
pubmed: 33748738
Eur J Clin Invest. 2021 Apr;51(4):e13520
pubmed: 33583018
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33361342
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
BMJ Case Rep. 2021 Feb 4;14(2):
pubmed: 33542020
Crit Care Resusc. 2020 Apr 01;22(2):91-94
pubmed: 32227819
J Am Geriatr Soc. 2020 Oct;68(10):2179-2183
pubmed: 32638347
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
Sci Rep. 2020 Nov 26;10(1):20692
pubmed: 33244060
Infect Drug Resist. 2021 May 24;14:1893-1903
pubmed: 34079300
SN Compr Clin Med. 2020;2(7):874-876
pubmed: 32838138
J Infect. 2021 Feb;82(2):282-327
pubmed: 32800801
J Infect. 2021 Mar;82(3):399-406
pubmed: 33589297
Glob Public Health. 2020 Sep;15(9):1278-1291
pubmed: 32623959